Tag : plc

Latest News

Global Post-traumatic Stress Disorder (PSTD) Therapeutics Market 2020-2024 | Evolving Opportunities with AstraZeneca Plc and Azevan Pharmaceuticals Inc. | Technavio

Newsemia
LONDON–(BUSINESS WIRE)– #GlobalPosttraumaticStressDisorderTherapeuticsMarket–The post-traumatic stress disorder therapeutics market will grow by USD 909.86 million during 2020-2024 Source link...
Latest News

Renishaw Announces Completion of the Main Part of a Multi-Centre Clinical Trial Jointly Undertaken with Herantis Pharma plc for the Treatment of Parkinson’s Disease Patients

Newsemia
Renishaw, announces that its drug delivery device has played a critical role in the investigation CDNF as a treatment for Parkinson’s disease. Source link...
Latest News

Frequent and Persistent PLCG1 Mutations in Sezary Cells Directly Enhance PLC gamma 1 Activity and Stimulate NF kappa B, AP-1, and NFAT Signaling

Newsemia
Patel, VM; Flanagan, CE; Martins, M; Jones, CL; Butler, RM; Woollard, WJ; Bakr, FS; … Mitchell, TJ; + view all Patel, VM; Flanagan, CE; Martins,...
Latest News

Global Gynecological Cancers Therapeutics Market 2019-2023| Evolving Opportunities with AstraZeneca and GlaxoSmithKline plc | Technavio

Newsemia
LONDON–(BUSINESS WIRE)– #Biotechnology–The global gynecological cancers therapeutics market is poised to grow by USD 8.96 billion during 2019-2023, progressing at a CAGR of over 14%....
Latest News

INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Indivior plc

Newsemia
SAN FRANCISCO–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/Indivior?src=hash" target="_blank">#Indivior</a>–INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Upcoming Deadline in Class Action Securities Litigation Against Indivior plc Source link...
Latest News

Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance

Newsemia
DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc Reports Record 4Q18 and FY2018 Net Sales, Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance Source link...
Latest News

Global Sinus Dilation Devices Market to Surpass US$ 5.7 Billion by 2026, with Major Players like, Entellus Medical, Inc., Smith &amp; Nephew Plc., Acclarent, Inc., B. Braun Melsungen AG, and Medtronic Plc

Newsemia
SEATTLE–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CMI&amp;src=ctag" target="_blank"gt;$CMIlt;/agt; lt;a href="https://twitter.com/hashtag/BalloonSinuplastySystems?src=hash" target="_blank"gt;#BalloonSinuplastySystemslt;/agt;–According to Coherent Market Insights, the global sinus dilation devices market is valued at US$ 2.7 Billion in 2017,...
Latest News

ALLERGAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick &amp; Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. – AGN

Newsemia
NEW ORLEANS–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24AGN&amp;src=ctag" target="_blank"gt;$AGNlt;/agt; lt;a href="https://twitter.com/hashtag/AGN?src=hash" target="_blank"gt;#AGNlt;/agt;–Kahn Swick &amp; Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr.,...
Latest News

Takeda nimmt Stellung zur von der Europäischen Kommission vorgenommenen Überprüfung der laufenden 1. Phase der geplanten Übernahme von Shire plc

Newsemia
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) („Takeda“) gab heute die folgende Erklärung bezüglich seiner Gespräche mit der Europäischen Kommission („Kommission“) ab, die im...
Latest News

Takeda publica comentarios sobre el análisis de la Comisión Europea de la primera fase de la adquisición propuesta de Shire plc

Newsemia
OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) dio a conocer hoy la siguiente declaración respecto de las tratativas con la Comisión Europea (CE)...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy